From GlobeNewswire: 2025-06-21 08:00:00

Perspective Therapeutics, Inc. announced two presentations at the SNMMI 2025 Annual Meeting. One presentation focused on dosimetry in patients with SSTR2-positive tumors using [212Pb]VMT-α-NET, while the other discussed the development of [68Ga]PSV377 for PET imaging. Both presentations highlighted promising results for cancer treatments (Globe Newswire).

The findings from the dosimetry sub-study suggest that [212Pb]VMT-α-NET is well-tolerated and shows potential efficacy in patients with neuroendocrine tumors. Additionally, the development of [68Ga]PSV377 as a PET imaging agent for tumors expressing FAP-α is showing strong affinity and uptake in preclinical models and human patients (Globe Newswire).

Perspective Therapeutics, Inc. is pioneering advanced cancer treatments using radiopharmaceuticals like [212Pb]VMT-α-NET and [68Ga]PSV377. The company’s innovative approach combines targeted therapy with personalized imaging diagnostics to optimize patient outcomes and minimize toxicity, offering hope for improved cancer treatments (Globe Newswire). Perspective Therapeutics is pioneering advanced cancer treatments with promising results, utilizing a proprietary technology to target cancer cells with radiation. Their approach combines imaging diagnostics and therapy to personalize treatment and improve patient outcomes. The company aims to expand its network to deliver patient-ready products for clinical trials and commercial use. However, forward-looking statements indicate potential risks and uncertainties that may impact actual results. For more information, contact Annie J. Cheng, CFA at [email protected] or Nic Johnson at [email protected].



Read more at GlobeNewswire: Perspective Therapeutics Presents at the Society of Nuclear